Virtu KCG Holdings’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
Sell
-13,615
Closed -$1.13M 3661
2014
Q4
$1.13M Buy
13,615
+781
+6% +$64.7K 0.02% 834
2014
Q3
$1.08M Sell
12,834
-558
-4% -$45.1K 0.02% 891
2014
Q2
$1.09M Sell
13,392
-2,790
-17% -$219K 0.02% 1098
2014
Q1
$1.23M Sell
16,182
-2,344
-13% -$171K 0.02% 1068
2013
Q4
$1.33M Buy
18,526
+7,701
+71% +$535K 0.01% 956
2013
Q3
$744K Buy
+10,825
New +$716K 0.01% 1510

Other funds holding NVS

Virtu KCG Holdings's NVS Position: Q2 2017 in Review

Virtu KCG Holdings increased its Novartis (NVS) stake by 421% in Q2 2017, buying an estimated $3.66M and bringing the position to 63,895 shares worth $4.78M. The position accounts for 0.13% of the portfolio, ranked #67.

Virtu KCG Holdings first reported a position in NVS in Q3 2013 and has held it in 16 quarters since. The position peaked at $52.2M in Q1 2014. 920 funds tracked by Wall St. Rank hold NVS as of Q2 2017.

  • Virtu KCG Holdings held 63,895 shares of Novartis worth $4.78M as of Q2 2017.
  • Virtu KCG Holdings bought 51,638 Novartis shares in Q2 2017, an estimated $3.66M.
  • Novartis made up 0.13% of Virtu KCG Holdings's portfolio in Q2 2017, its #67 holding.
  • Virtu KCG Holdings first reported a position in Novartis in Q3 2013 and has held it in 16 quarters since.
  • Virtu KCG Holdings's Novartis position peaked at $52.2M in Q1 2014.
  • 920 funds tracked by Wall St. Rank held Novartis as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.